Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.
Apalutamide for metastatic, castration-sensitive prostate cancer / Chi, K.N., Agarwal, N., Bjartell, A., Chung, B.H., Pereira de Santana Gomes, A.J., Given, R., Juárez Soto, Á., Merseburger, A.S., Özgüroğlu, M., Uemura, H., Ye, D., Deprince, K., Naini, V., Li, J., Cheng, S., Yu, M.K., Zhang, K.e., Larsen, J.S., Mccarthy, S., Chowdhury, S., et al.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 381:1(2019), pp. 13-24. [10.1056/NEJMoa1903307]
Apalutamide for metastatic, castration-sensitive prostate cancer
Sciarra AlessandroMembro del Collaboration Group
2019
Abstract
Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong radiographic progression-free survival and overall survival as compared with placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer has not been determined.| File | Dimensione | Formato | |
|---|---|---|---|
|
Kim_Apalutamide_2019.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
234.73 kB
Formato
Adobe PDF
|
234.73 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
